drugset / Trial / NCT03574649
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a randomized phase 2 study to compare the efficacy of neoadjuvant, consolidation, and adjuvant immunotherapy (NANT NSCLC Combination Immunotherapy; experimental arm) to standard of care (surgery and adjuvant chemotherapy; control arm) in subjects with stage II-IIIa resectable NSCLC.
Timeline
- Start
- 2018-06
- Primary completion
- 2018-08
- Completion
- 2018-08-22
Outcome
Outcome not reported
Stopped: “Trial not initiated”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aldoxorubicin | Small molecule | — | — |
| Subject | Avelumab | Monoclonal antibody | — | — |
| Comparator | Carboplatin | Small molecule | — | — |
| Subject | Cyclophosphamide | Other / unclassified | — | — |
| Comparator | Docetaxel | Small molecule | — | — |
| Subject | ETBX-011 | Vaccine | — | — |
| Subject | ETBX-051 | Vaccine | — | — |
| Subject | ETBX-061 | Vaccine | — | — |
| Subject | GI-4000 | Vaccine | — | — |
| Subject | GI-6301 | Vaccine | — | — |
| Subject | N-803 | Protein / enzyme biologic | — | — |
| Subject | fluorouracil | Small molecule | — | — |
| Subject | haNK | Cell therapy | — | Intravenous |
| Background | Cisplatin | Other / unclassified | — | — |
| Background | Nab-paclitaxel | Small molecule | — | — |